Condition: Tubular Breast Cancer · Mucinous Breast Cancer · Invasive Duct Carcinoma of Breast · Sponsor: RenJi Hospital
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
This description comes directly from the study's public registry record.
Yueyao Du, M.D. · 86-21-68385569 · jessicayy8629@126.com
Jie Zhang, M.D. · 86-21-68385516 · doudou090227@163.com
Always discuss trial participation with your own doctor first.
| Renji Hospital, School of Medicine, Shanghai Jiaotong University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03201861